Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation. The findings were presented in a poster at the… Read More
Takeda has announced the decision to discontinue its cell therapy efforts, as part of a “strategic portfolio prioritisation process”. The company plans to find an external partner to take over its cell therapy platform technologies and research and clinic-ready programmes in this field. According to… Read More
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist. It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose… Read More
A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease. AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing,… Read More
A new study has revealed an important clue as to why immunotherapy fails in many patients with cancer. The study, led by researchers from the University of Birmingham supported by the National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre and the University of… Read More
The Association of the British Pharmaceutical Industry (ABPI) and the UK government have been unable to reach an agreement on changes to a controversial medicines payment scheme. In April 2025, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme… Read More
The US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4mg) as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). The approval is in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a… Read More
Viking Therapeutics has released positive top-line results from its Phase II clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for… Read More
A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink. CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells. … Read More
In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL). QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More
The pharmaceutical industry is on high alert as US President Donald Trump proposes a 200-250% tariff on drug imports, which could significantly increase prices and reduce profit margins. While the tariffs are set to be announced soon, a grace period of 12 to 18 months has been… Read More
Scientists have discovered that people diagnosed with ME/CFS have significant differences in their DNA, offering the first robust evidence that genes contribute to a person’s chance of developing the disease. Initial findings have uncovered eight areas of genetic code in people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome)… Read More
The US Department of Health and Human Services (HHS) has announced the beginning of a “coordinated wind-down” of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA). The department says the decision follows a comprehensive review of mRNA-related investments initiated during the… Read More
A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery. The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More
US President Donald Trump has sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash US prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed an executive order in May demanding drugmakers… Read More
GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia. Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More
